NCT05459753View on ClinicalTrials.gov

Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)

NAActive, not recruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Parkinson DiseaseProgressive Supranuclear Palsy
Interventions
RADIATION

(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET

Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.

RADIATION

Dihydrotetrabenazine (DTBZ) PET

Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.

Trial Locations (1)

48106

University of Michigan - Michigan Medicine, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Michigan

OTHER